Abstract
While selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), approximately 40% of patients fail to respond to SSRIs. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that might be effective in the treatment of OCD, even among those who have failed previous SSRI trials. Thirty-nine patients who met DSM-IV criteria for OCD, including 29 who were resistant to prior SRI treatment trials, were treated with venlafaxine in an open, naturalistic fashion. Improvement was assessed using the Clinical Global Impressions-Improvement scale. Of 39 patients treated with venlafaxine, 27 (69.2%) were rated as sustained treatment responders. Of the 29 patients who did not respond to 1 or more previous SRI trials, 22 (75.9%) were rated as having sustained response to treatment. Mean dose of venlafaxine was 232.2 mg/day (range, 37.5-375 mg/day), and it was generally well tolerated. Venlafaxine may be beneficial to individuals with OCD, including those who have not responded to prior SSRI trials. However, these findings must be interpreted with caution, as the study is limited by its open, retrospective nature and its inclusion of patients with comorbid diagnoses and pa...Continue Reading
Citations
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Christopher PittengerVladimir Coric
Jun 2, 2009·Clinical Neuropharmacology·Yi-Wei YehHui-Ming Feng
Jul 28, 2011·Molecular Pharmacology·Van A DozeDianne M Perez
Dec 7, 2007·Biological & Pharmaceutical Bulletin·Yumi SugimotoJun Yamada
Aug 26, 2014·The Psychiatric Clinics of North America·Christopher Pittenger, Michael H Bloch
Mar 23, 2007·Expert Opinion on Pharmacotherapy·Leonardo F FontenelleMarcio Versiani
Oct 6, 2004·Expert Opinion on Pharmacotherapy·Kelda H Walsh, Christopher J McDougle
Nov 26, 2011·Biological Psychiatry·Bruno AouizeratePierre Burbaud
Aug 18, 2010·Behavioural Brain Research·Sokichi HondaKazuo Takahama
May 3, 2006·The Psychiatric Clinics of North America·Damiaan Denys
Dec 31, 2009·Human Psychopharmacology·Bernardo Dell'OssoA Carlo Altamura
Oct 28, 2004·European Journal of Pharmacology·Junichi MiyamotoTeruhiko Matsumiya
Mar 1, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Stefano Pallanti, Leonardo Quercioli
Dec 9, 2004·The Annals of Pharmacotherapy·Nicole J Phelps, Marshall E Cates
Apr 12, 2014·International Clinical Psychopharmacology·Sanjaya Saxena, Jennifer Sumner
Dec 6, 2018·Journal of Clinical Psychopharmacology·Srinivas BalachanderY C Janardhan Reddy
Mar 3, 2005·Acta Psychiatrica Scandinavica·K SchruersE Griez
Jan 1, 2014·Expert Review of Neurotherapeutics·Shyam Sundar Arumugham, Y C Janardhan Reddy
Aug 14, 2018·Current Neuropharmacology·Antonio Del CasaleMaurizio Pompili
Mar 4, 2020·Phytotherapy Research : PTR·Zahra AyatiRoja Rahimi
Jan 1, 2014·SAGE Open Medical Case Reports·Maria S SignorelliEugenio Aguglia
Aug 11, 2004·CNS Spectrums·Olga Brawman-Mintzer, Kimberly A Yonkers
Nov 3, 2004·CNS Spectrums·David S Husted, Nathan A Shapira
Jan 30, 2008·CNS Spectrums·Andrea AllenEric Hollander